Literature DB >> 12039412

HLA-DR and HLA-DQ polymorphism in human thyroglobulin-induced autoimmune thyroiditis: DR3 and DQ8 transgenic mice are susceptible.

Qiang Wan1, Rajal Shah, John C Panos, Alvaro A Giraldo, Chella S David, Yi chi M Kong.   

Abstract

In contrast to H2-based susceptibility to experimental autoimmune thyroiditis (EAT) induced with thyroglobulin (Tg), human leukocyte antigen (HLA) association with Hashimoto's thyroiditis, the human counterpart, is less clear, and determining association is further complicated by DR/DQ linkage disequilibrium. Previously, we addressed the controversial implication of HLA-DR genes by introducing HLA-DRA/DRB1*0301 (DR3) transgene into endogenous class II negative H2Ab(0) mice. EAT induction with either human (h) or mouse (m) Tg demonstrated the permissiveness of DR3 molecules for shared Tg epitopes. Here, we examined the participation of HLA-DQ genes by introducing DQA1*0301/DQB1*0302 (DQ8) transgene into class II negative Ab(0) or class I and II negative beta(2)m((-/-)) Ab(0) mice. About 50% and 80% of HLA-DQ8(+) Ab(0) and beta(2)m(-) Ab(0) mice, respectively, developed moderate EAT after hTg immunization, but only minimal response to mTg. The hTg presentation to hTg-primed cells was blocked by anti-DQ mAb in vitro. By contrast, HLA-DRB1*1502 (DR2) and *0401 (DR4) transgenes contributed little to hTg induction. Similarly, DQA1*0103/DQB1*0601 or DQA1*0103/DQB1*0602 (DQ6) transgenic Ab(0) mice were unresponsive to hTg induction and carried no detectable influence in DQ8/DQ6 double transgenic mice. Thus, both HLA-DR and -DQ polymorphism exists for hTg in autoimmune thyroiditis. The use of defined single or double transgenic mice obviates the complications seen in polygenic human studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12039412     DOI: 10.1016/s0198-8859(02)00360-9

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  8 in total

1.  Efficacy of HLA-DRB1∗03:01 and H2E transgenic mouse strains to correlate pathogenic thyroglobulin epitopes for autoimmune thyroiditis.

Authors:  Yi-chi M Kong; Nicholas K Brown; Jeffrey C Flynn; Daniel J McCormick; Vladimir Brusic; Gerald P Morris; Chella S David
Journal:  J Autoimmun       Date:  2011-06-17       Impact factor: 7.094

2.  Depletion of CD4+CD25+ regulatory T cells exacerbates sodium iodide-induced experimental autoimmune thyroiditis in human leucocyte antigen DR3 (DRB1*0301) transgenic class II-knock-out non-obese diabetic mice.

Authors:  J C Flynn; C Meroueh; D P Snower; C S David; Y M Kong
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

3.  Superiority of thyroid peroxidase DNA over protein immunization in replicating human thyroid autoimmunity in HLA-DRB1*0301 (DR3) transgenic mice.

Authors:  J C Flynn; A Gardas; Q Wan; M Gora; G Alsharabi; W Z Wei; A A Giraldo; C S David; Y M Kong; J P Banga
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

Review 4.  What can the HLA transgenic mouse tell us about autoimmune diabetes?

Authors:  F S Wong; L Wen
Journal:  Diabetologia       Date:  2004-09-02       Impact factor: 10.122

Review 5.  Thyroglobulin as an autoantigen: what can we learn about immunopathogenicity from the correlation of antigenic properties with protein structure?

Authors:  Fabrizio Gentile; Marisa Conte; Silvestro Formisano
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

Review 6.  Autoimmune thyroiditis: a model uniquely suited to probe regulatory T cell function.

Authors:  Yi-Chi M Kong; Gerald P Morris; Nicholas K Brown; Yan Yan; Jeffrey C Flynn; Chella S David
Journal:  J Autoimmun       Date:  2009-10-12       Impact factor: 7.094

7.  The genetic basis of graves' disease.

Authors:  Rafał Płoski; Konrad Szymański; Tomasz Bednarczuk
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

8.  Immunogenetics of Hashimoto's thyroiditis.

Authors:  Dimitry A Chistiakov
Journal:  J Autoimmune Dis       Date:  2005-03-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.